Halozyme Therapeutics - 53 Year Dividend History | HALO

Historical dividend payout and yield for Halozyme Therapeutics (HALO) since 1971. The current TTM dividend payout for Halozyme Therapeutics (HALO) as of July 24, 2024 is $0.00. The current dividend yield for Halozyme Therapeutics as of July 24, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $7.019B $0.829B
Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.
Stock Name Country Market Cap PE Ratio